Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
Feb. 25, 2021—A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes.
Feb. 11, 2021—David Merryman has discovered that targeting a protein receptor in heart cells may limit a heart attack’s acute and long-term effects.
American Chemical Society appoints Craig Lindsley editor in chief of ‘Journal of Medicinal Chemistry’
Dec. 14, 2020—Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of chemistry, pharmacology and biochemistry, has been named editor in chief of the "Journal of Medicinal Chemistry." His appointment will begin Jan. 1.
Oct. 20, 2020—Craig Lindsley, the William K. Warren, Jr. Chair and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, effective Dec. 1, 2020.
Jul. 23, 2020—VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease.
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Jun. 16, 2020—Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia.
Leader in Vanderbilt drug discovery efforts, Craig Lindsley named interim editor-in-chief of ACS Pharmacology & Translational Science
Jun. 12, 2020—Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science."
Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders
May. 5, 2020—Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs.
Jan. 4, 2019—Craig Lindsley, co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been named a fellow of the National Academy of Inventors.
Dec. 21, 2018—Chancellor Nicholas S. Zeppos reflects on Vanderbilt's work, progress and accomplishments over the past 12 months in his final column of 2018.
Dec. 11, 2018—Craig W. Lindsley, William K. Warren Jr. Professor of Medicine and co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been elected a fellow of the prestigious National Academy of Inventors.
Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.